Oncoclinicas do Brasil Servicos Medicos S.A.

Oncoclinicas do Brasil Servicos Medicos SA's next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Oncoclinicas do Brasil Servicos Medicos SA has 1.12B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.18, and the price-to-book ratio stands at 83.90.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.04 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Oncoclinicas do Brasil Servicos Medicos SA trades at an EV/FCF ratio of 3.97, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of June 30, 2026, Oncoclinicas do Brasil Servicos Medicos SA maintains a current ratio of 0.44, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3,885.39, indicating elevated leverage, while an interest coverage ratio of -5.12 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Oncoclinicas do Brasil Servicos Medicos SA posted a negative return on equity (ROE) of -290.65, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -49.33, reflecting losses generated across the asset base. Inventory turnover of 16.96 indicates how many times Oncoclinicas do Brasil Servicos Medicos SA sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Oncoclinicas do Brasil Servicos Medicos SA's stock has declined approximately 52.83% over the past 52 weeks. The 50-day moving average sits at 1.13, while the 200-day moving average is 1.50.

Over the twelve months ended June 30, 2026, Oncoclinicas do Brasil Servicos Medicos SA posted a gross margin of 27.31, reflecting its pricing power and cost economics. The operating margin of -62.87 and net profit margin of -83.55 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. The dividend payout ratio of -0.66 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 68.14, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 39.75, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Oncoclinicas do Brasil Servicos Medicos SA shareholders.

Oncoclinicas do Brasil Servicos Medicos SA's most recent stock split took place on October 9, 2025 with a 128:133 split ratio.

As of June 30, 2026, Oncoclinicas do Brasil Servicos Medicos SA has an Altman Z-Score of -4.02, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.